EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

HDAC inhibition sensitizes pancreatic tumors to DNA damage by global redistribution of the transcriptional machinery

Gaoyang Liang, Hung V-T Nguyen, Jonathan Zhu, Hervé Tiriac, Hadiqa Zafar, Daniel Y Cao, Gabriela Estepa iD, Dylan C Nelson, Yang Dai, Tae Gyu Oh, Christopher Liddle iD, Ruth T Yu und 10 weitere

Proceedings of the National Academy of Sciences · 30.06.2026 · 123 (26)

DOI: 10.1073/pnas.2536040123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 25.06.2026. Verfasst von Gaoyang Liang und 21 weiteren Autor:innen. Beteiligte Einrichtung: Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, CA 92037. Hauptthemen laut MEDLINE: DNA Damage, Histone Deacetylase Inhibitors, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Paul M. Angell Family Foundation (PMAFF), HHS | NIH | National Cancer Institute (NCI), NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The DNA damage response (DDR) is critical for pancreatic ductal adenocarcinoma (PDAC) development and therapeutic responses, including to genotoxic agents. While epigenetic modulators have been shown to contribute to the DDR, how chromatin regulation dictates responses to DNA damage in PDAC remains incompletely understood. Here, we identify Class I histone deacetylases (HDACs) as critical regulators of the DDR. HDAC1/2 direct the genomic distribution of H3K27ac, ensuring sufficient BRD4 and RNA polymerase II (Pol II) occupancy at DDR gene promoters. HDAC inhibition by entinostat shifts the balance of H3K27 acetylation preferentially toward intergenic regions, diverting BRD4 and Pol II from promoters, thereby suppressing DDR gene expression. In line with this, HDAC inhibition heightens DNA damage and sensitizes PDAC to diverse DNA-damaging and DDR-targeting agents. Since the clinical development of HDAC inhibitors has been limited by systemic toxicity, we developed bottlebrush prodrug (BPD) nanoparticles for tumor-selective entinostat delivery. Entinostat-BPD achieved tumor-specific HDAC inhibition while displaying potent efficacy and reduced systemic toxicity. These findings reveal an HDAC-dependent DDR vulnerability and offer combinational and precision targeting strategies to facilitate clinical translation and improve PDAC patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA DamageHistone Deacetylase InhibitorsPancreatic NeoplasmsCarcinoma, Pancreatic DuctalTranscription, GeneticHumansBenzamidesAnimalsPyridinesCell Line, TumorTranscription FactorsCell Cycle ProteinsHistone Deacetylase 1Histone Deacetylase 2HistonesGene Expression Regulation, NeoplasticRNA Polymerase IIMiceNuclear ProteinsAcetylationProdrugsBromodomain Containing Proteins

Stichwörter der Autor:innen

DNA damage responseHDACHDAC inhibitorbottlebrush prodrugpancreatic cancer

Substanzen

Histone Deacetylase InhibitorsBenzamidesPyridinesentinostatTranscription FactorsCell Cycle ProteinsHistone Deacetylase 1BRD4 protein, humanHistone Deacetylase 2Histones

Autor:innen und Institutionen

  • Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, CA 92037.
  • Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139.
  • Thayer School of Engineering, Dartmouth College, Hanover, NH 03755.
  • Division of Surgical Oncology, Department of Surgery, Moores Cancer Center, University of California San Diego, La Jolla, CA 92093.
  • Storr Liver Centre, Westmead Institute for Medical Research and Sydney Medical School, University of Sydney, Westmead, NSW 2145, Australia.
  • Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, CA 92037.

ORCID-Profile: Gabriela Estepa, Christopher Liddle, Tony Hunter, Reuben Shaw, Annette R Atkins, Jeremiah A Johnson, Michael Downes, Ronald M Evans

Förderung

  • Paul M. Angell Family Foundation (PMAFF)
  • HHS | NIH | National Cancer Institute (NCI)
  • NIA NIH HHS
  • NCI NIH HHS
  • NOMIS Stiftung (NOMIS Foundation)
  • David C. Copley Foundation (DCC)
  • March of Dimes Foundation (MDF)
  • Lustgarten Foundation (Lustgarten)

Zitieren

APA

Liang, G., Nguyen, H. V., Zhu, J., Tiriac, H., Zafar, H., Cao, D. Y., Estepa, G., Nelson, D. C., Dai, Y., Oh, T. G., Liddle, C., Yu, R. T., Hunter, T., Engle, D., Shaw, R., Lowy, A. M., Fan, W., Truitt, M. L., Atkins, A. R., …, & Evans, R. M. (2026). HDAC inhibition sensitizes pancreatic tumors to DNA damage by global redistribution of the transcriptional machinery. Proceedings of the National Academy of Sciences, 123(26). https://doi.org/10.1073/pnas.2536040123

Vancouver

Liang G, Nguyen HV, Zhu J, Tiriac H, Zafar H, Cao DY, et al. HDAC inhibition sensitizes pancreatic tumors to DNA damage by global redistribution of the transcriptional machinery. Proceedings of the National Academy of Sciences. 2026;123(26). doi:10.1073/pnas.2536040123

BibTeX
@article{Liang2026,
  author = {Liang, Gaoyang and Nguyen, Hung V-T and Zhu, Jonathan and Tiriac, Hervé and Zafar, Hadiqa and Cao, Daniel Y and Estepa, Gabriela and Nelson, Dylan C and Dai, Yang and Oh, Tae Gyu and Liddle, Christopher and Yu, Ruth T and Hunter, Tony and Engle, Dannielle and Shaw, Reuben and Lowy, Andrew M and Fan, Weiwei and Truitt, Morgan L and Atkins, Annette R and Johnson, Jeremiah A and Downes, Michael and Evans, Ronald M},
  title = {HDAC inhibition sensitizes pancreatic tumors to DNA damage by global redistribution of the transcriptional machinery},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  volume = {123},
  number = {26},
  doi = {10.1073/pnas.2536040123}
}
Kostenlos starten →